您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > STM2457
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
STM2457
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
STM2457图片
规格:98%
分子量:444.53
包装与价格:
包装价格(元)
5mg电议
10mg电议
50mg电议

产品介绍
STM2457 是一流的、高效、选择性和口服活性的 METTL3 抑制剂,IC50 为 16.9 nM。 STM2457可用于急性髓性白血病(AML)的研究。
货号:ajcx12022
CAS:2499663-01-1
分子式:C25H28N6O2
分子量:444.53
溶解度:DMSO : 270 mg/mL
纯度:98%
存储:Store at -20°C
库存:现货

Background:

STM2457, an inhibitor of METTL3-METTL14 catalytic activity with IC50of 16.9 nM, can directly bind to the METTL3-METTL14 with a high affinity (Kd) of 1.4 nM. STM2457, also shows greater than 1,000-fold selectivity for METTL3 compared to other RNA, DNA and protein methyltransferases.[1]

STM2457 can inhibit the proliferation of human AML cells but not normal non-lekaemic haemopoietic cells. What’s more, STM2457 can reduce the clonogenic potential of primary mouse AML cells and inhibit METTL3 in MOLM-13 cells, which causes myeloid differentiation and cell cycle arrest.[1]

STM2457 can impair engraftment and AML expansionin vivoand significantly prolong the mouse lifespan. It also reduces human CD45+cells in the bone marrow and spleen.[1]

参考文献:
[1] Yankova, E., Blackaby, W., Albertella, M. et al. Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia. Nature 593, 597–601 (2021).

Protocol:

Kinase experiment [1]:

Inhibition of METTL3-METTL14

STM2457 inhibits METTL3-METTL14 activity with IC50 of 16.9 nM.

Cell experiment [1]:

Cell lines

Human AML cells, mouse AML cells, MOLM-13

Preparation method

The solubility of this compound in DMSO is > 1 mM.

Reaction Conditions

3 days

Applications

STM2457 shows its anti-leukaemic activity by the pharmacological inhibition of METTL3 on SP1 and BRD4.

Animal experiment [1]:

Animal models

NSG mice (primary murine MLL-AF9/Flt3ITD/+)

Dosage form

50 mg/kg, intraperitoneal injection, STM2457 was dissolved in 20% (w/v) 2-hydroxyprolpy β-cyclodextrin vehicle.

Applications

STM2457 decrease total m6A levels on poly-A+-enriched RNA of METTL3, reduces human CD45+cells in the bone marrow and spleen and impair engraftment and AML expansion in vivo at the dose of 50 mg/kg.

参考文献:

[1]. Yankova, E., Blackaby, W., Albertella, M. et al. Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia. Nature 593, 597–601 (2021).